{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:04:13Z","timestamp":1760821453910},"reference-count":44,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14293","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T13:08:03Z","timestamp":1708348083000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of nab\u2011paclitaxel vs. Gemcitabine in combination with S\u20111 for advanced pancreatic cancer: A multicenter phase II randomized trial"],"prefix":"10.3892","volume":"27","author":[{"given":"Xi","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaolin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongyuan","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lie","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junwei","family":"Wu","sequence":"additional","affiliation":[{"name":"Oncology Department, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deliang","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Oncology Department, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Oncology Department, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yefei","family":"Rong","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayong","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenchuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minzhi","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Clinical Research Unit, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuzhong","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Radiology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Anti\u2011tumor Business, Shi Yao Group European Pharmaceutical Co., Ltd., Shijiazhuang, Hebei 050035, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dansong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiantao","family":"Kuang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenquan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"key20240322100341_b1-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"key20240322100341_b2-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"key20240322100341_b3-ol-27-4-14293","first-page":"135","article-title":"The American Cancer Society's facts & figures: 2020 Edition","volume":"11","author":"Viale","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"key20240322100341_b4-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"key20240322100341_b5-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"key20240322100341_b6-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2015.12.026","article-title":"Current standards and new innovative approaches for treatment of pancreatic cancer","volume":"57","author":"Conroy","year":"2016","journal-title":"Eur J Cancer"},{"key":"key20240322100341_b7-ol-27-4-14293","article-title":"Clinical Practice Guidelines in Oncology","volume-title":"Pancreatic Adenocarcinoma","author":"National Comprehensive Cancer Network (NCCN)","year":"2022"},{"key":"key20240322100341_b8-ol-27-4-14293","volume-title":"Guidelines of The Chinese Society of Clinical Oncology (CSCO) pancreatic cancer 2020","author":"CSCO","year":"2020"},{"key":"key20240322100341_b9-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"key20240322100341_b10-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"key20240322100341_b11-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jncc.2022.08.006","article-title":"Chinese society of clinical oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer","volume":"2","author":"Cui","year":"2022","journal-title":"J National Cancer Center"},{"key":"key20240322100341_b12-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: Outcomes from the CONKO-003 trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20240322100341_b13-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2022.06.010","article-title":"Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial","volume":"174","author":"Ohba","year":"2022","journal-title":"Eur J Cancer"},{"key":"key20240322100341_b14-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2021.08.002","article-title":"Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)","volume":"157","author":"Go","year":"2021","journal-title":"Eur J Cancer"},{"key":"key20240322100341_b15-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1200\/jco.2013.31.15_suppl.e15109","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20240322100341_b16-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"key20240322100341_b17-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00280-007-0514-8","article-title":"A late phase II study of S-1 for metastatic pancreatic cancer","volume":"61","author":"Okusaka","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20240322100341_b18-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/sj.bjc.6603168","article-title":"Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer","volume":"94","author":"Nakamura","year":"2006","journal-title":"Br J Cancer"},{"key":"key20240322100341_b19-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/jjco\/hyr090","article-title":"Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer","volume":"41","author":"Ueno","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"key20240322100341_b20-ol-27-4-14293","first-page":"2109","article-title":"Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer (2018 edition)","volume":"34","author":"Zhao","year":"2018","journal-title":"J Clin Hepatol"},{"key":"key20240322100341_b21-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00280-013-2265-z","article-title":"Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer","volume":"72","author":"Song","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20240322100341_b22-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/annonc\/mdn661","article-title":"Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531)","volume":"20","author":"Roy","year":"2009","journal-title":"Ann Oncol"},{"key":"key20240322100341_b23-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"key20240322100341_b24-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): Results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J Thorac Oncol"},{"key":"key20240322100341_b25-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00280-018-3611-y","article-title":"Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer","volume":"82","author":"Tahara","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20240322100341_b26-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/jso.24147","article-title":"S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model","volume":"113","author":"Suenaga","year":"2016","journal-title":"J Surg Oncol"},{"key":"key20240322100341_b27-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MPA.0000000000000501","article-title":"Nab-Paclitaxel plus S-1 shows increased antitumor activity in patient-derived pancreatic cancer xenograft mouse models","volume":"45","author":"Li","year":"2016","journal-title":"Pancreas"},{"key":"key20240322100341_b28-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00280-018-3650-4","article-title":"Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: A single-arm phase II trial","volume":"82","author":"Zhang","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20240322100341_b29-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"92401","DOI":"10.18632\/oncotarget.21359","article-title":"Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): A single arm, single center, phase II trial","volume":"8","author":"Shi","year":"2017","journal-title":"Oncotarget"},{"key":"key20240322100341_b30-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"17588359221118020","DOI":"10.1177\/17588359221118020","article-title":"Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: Results of a multicenter, randomized, phase III trial (GAPSO study)","volume":"14","author":"Dai","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"key20240322100341_b31-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.clbc.2020.07.012","article-title":"Phase 1 Dose-Escalation study of triweekly Nab-Paclitaxel combined with S-1 for HER2-Negative metastatic breast cancer","volume":"20","author":"Morimoto","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"key20240322100341_b32-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u2018personalized\u2019 approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"key20240322100341_b33-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20240322100341_b34-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"key20240322100341_b35-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/jjco\/hyy063","article-title":"Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer","volume":"48","author":"Xu","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"key20240322100341_b36-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00432-020-03442-0","article-title":"Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: A randomized study","volume":"147","author":"Zong","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20240322100341_b37-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/cncr.22559","article-title":"Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma","volume":"109","author":"Lee","year":"2007","journal-title":"Cancer"},{"key":"key20240322100341_b38-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s00535-012-0664-2","article-title":"Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer","volume":"48","author":"Ogura","year":"2013","journal-title":"J Gastroenterol"},{"key":"key20240322100341_b39-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-21-3581","article-title":"Molecular characterization of KRAS Wild-type tumors in patients with pancreatic adenocarcinoma","volume":"28","author":"Philip","year":"2022","journal-title":"Clin Cancer Res"},{"key":"key20240322100341_b40-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41565-021-00897-1","article-title":"Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer","volume":"16","author":"Li","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"key20240322100341_b41-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000086771","article-title":"An early phase II study of S-1 in patients with metastatic pancreatic cancer","volume":"68","author":"Ueno","year":"2005","journal-title":"Oncology"},{"key":"key20240322100341_b42-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1200\/JCO.2007.15.2090","article-title":"Potential regional differences for the tolerability profiles of fluoropyrimidines","volume":"26","author":"Haller","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20240322100341_b43-ol-27-4-14293","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1349-7006.2010.01793.x","article-title":"Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients","volume":"102","author":"Chuah","year":"2011","journal-title":"Cancer Sci"},{"key":"key20240322100341_b44-ol-27-4-14293","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T08:04:40Z","timestamp":1711094680000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2,19]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14293","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"article-number":"161"}}